Innovative Therapeutics Shattuck Labs is focused on developing first-in-class antibody therapies targeting TNF receptors for inflammatory and autoimmune diseases, presenting opportunities for collaboration in advanced biologics and protein engineering.

Active Industry Engagement The company's active participation in major gastroenterology conferences like UEGW, ECCO, and Crohn's and Colitis Congress indicates ongoing engagement and potential avenues for partnerships, visibility, and clinical trial collaborations.

Strong Funding & Growth With over $103 million in funding and a revenue range of up to $10 million, Shattuck is investing heavily in research and development, creating opportunities for strategic investment, joint ventures, or supply agreements for innovative therapeutics.

Research & Development Focus Shattuck's expertise in protein engineering and immunology positions it well for collaborations in R&D, particularly with organizations seeking advanced biologics for inflammatory diseases, opening doors for technology licensing and joint development.

Emerging Market Presence Located in Austin and Durham with a growing profile in biotech conferences, Shattuck offers potential for partnerships in clinical research, drug development, and commercialization within the autoimmune therapeutics market.